These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 31563241)
1. Pilot Study Comparing the Efficacy, Safety, Convertibility, and Tacrolimus Trough Levels of Twice-Daily Tacrolimus (Prograf) to Once-Daily Tacrolimus (Advagraf) Among Standard-Risk Kidney Transplant Patients at the National Kidney and Transplant Institute. Danguilan RA; Lamban A; Pamugas GEP Transplant Proc; 2019 Oct; 51(8):2615-2619. PubMed ID: 31563241 [TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Staatz CE; Tett SE Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595 [TBL] [Abstract][Full Text] [Related]
4. Once- versus twice-daily tacrolimus: are the formulations truly equivalent? Barraclough KA; Isbel NM; Johnson DW; Campbell SB; Staatz CE Drugs; 2011 Aug; 71(12):1561-77. PubMed ID: 21861541 [TBL] [Abstract][Full Text] [Related]
5. Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment. Ma MK; Kwan LP; Mok MM; Yap DY; Tang CS; Chan TM Ren Fail; 2013 Aug; 35(7):942-5. PubMed ID: 23815459 [TBL] [Abstract][Full Text] [Related]
6. Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients. Wu SW; Tsai HC; Tsai PY; Hung TW; Chang HR; Lian JD Swiss Med Wkly; 2013; 143():w13850. PubMed ID: 23986367 [TBL] [Abstract][Full Text] [Related]
7. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial. Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956 [TBL] [Abstract][Full Text] [Related]
8. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study. Melo MJ; Gonçalves J; Guerra JO; Santana A; Nascimento C Transplant Proc; 2015 May; 47(4):911-3. PubMed ID: 26036484 [TBL] [Abstract][Full Text] [Related]
9. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. Jannot M; Masson I; Alamartine E; Mariat C Ann Transplant; 2014 Jul; 19():320-4. PubMed ID: 24999809 [TBL] [Abstract][Full Text] [Related]
10. A single center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single). Yang SS; Choi JY; Cho WT; Park JB; Kim SJ Transplant Proc; 2015 Apr; 47(3):617-21. PubMed ID: 25891697 [TBL] [Abstract][Full Text] [Related]
11. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation. Iaria G; Sforza D; Angelico R; Toti L; de Luca L; Manuelli M; Bellini I; Manzia TM; Anselmo A; Tisone G Transplant Proc; 2011 May; 43(4):1028-9. PubMed ID: 21620043 [TBL] [Abstract][Full Text] [Related]
12. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Crespo M; Mir M; Marin M; Hurtado S; Estadella C; Gurí X; Rap O; Moral R; Puig JM; Lloveras J Transplant Proc; 2009; 41(6):2115-7. PubMed ID: 19715848 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202 [TBL] [Abstract][Full Text] [Related]
15. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K; Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860 [TBL] [Abstract][Full Text] [Related]
16. The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients. Sukkha S; Chindavijak B; Nosoongnoen W; Phakdeekitchareon B; Kitiyakara C; Sumethkul V Drug Metab Pharmacokinet; 2020 Feb; 35(1):139-144. PubMed ID: 31727575 [TBL] [Abstract][Full Text] [Related]
17. Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature. Tran D; Vallée M; Collette S; Senécal L; Lafrance JP; Dandavino R; Boucher A Exp Clin Transplant; 2014 Aug; 12(4):323-7. PubMed ID: 24844288 [TBL] [Abstract][Full Text] [Related]